Filing Flows › Abbott Laboratories (ABT) › Q3 2026
Abbott Laboratories (ABT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Abbott Laboratories (ABT) reported revenue of $13.0B for the third quarter 2026 (Q3 2026), +14% from a year earlier and +3% from the quarter before. Operating margin was 10.4%, net earnings $920M (7.1% of revenue).
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.0B | +3% | +14% |
| Operating profit | $1.4B | -20% | -34% |
| Net earnings | $920M | -0.9% | -44% |
| Operating cash flow | $1.7B | -30% | -38% |
| Free cash flow | $1.2B | -39% | -47% |
What changed
Revenue was $13.0B in Q3 2026, up 14% year over year and up 3% from the previous quarter.
Operating profit was $1.4B, a 10.4% margin (down 7.7 points year over year). Operating profit fell $0.70B even though revenue rose $1.6B versus Q3 2025, so costs grew faster than sales. Total costs grew 25% against revenue growth of 14%. The fastest-growing cost line was Other operating costs (+100%). Net earnings were $0.92B, down 44% year over year. The effective tax rate was 25.3%.
Operating cash flow was $1.7B (down 38% year over year), 189% of net earnings. Non-cash charges added back $1.3B of depreciation and amortization and $0.14B of share-based compensation. Working capital and other items used $0.58B. Capital expenditures of $0.51B left free cash flow of $1.2B.
Questions
What was Abbott Laboratories' revenue in the third quarter 2026?
Abbott Laboratories (ABT) reported revenue of $13.0B for the third quarter 2026 (Q3 2026), +14% from a year earlier and +3% from the quarter before.
Was Abbott Laboratories profitable in the third quarter 2026?
Operating profit was $1.4B (10.4% of revenue) and net earnings $920M.